Logo image of TLPH

TALPHERA INC (TLPH) Stock Price, Quote, News and Overview

NASDAQ:TLPH - Nasdaq - US00444T2096 - Common Stock - Currency: USD

0.44  +0 (+0.59%)

TLPH Quote, Performance and Key Statistics

TALPHERA INC

NASDAQ:TLPH (7/16/2025, 2:25:25 PM)

0.44

+0 (+0.59%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High1.19
52 Week Low0.38
Market Cap9.02M
Shares20.50M
Float19.97M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-12 2025-08-12
IPO02-11 2011-02-11


TLPH short term performance overview.The bars show the price performance of TLPH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30

TLPH long term performance overview.The bars show the price performance of TLPH in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of TLPH is 0.44 USD. In the past month the price decreased by -10.73%. In the past year, price decreased by -49.72%.

TALPHERA INC / TLPH Daily stock chart

TLPH Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 57.35 747.92B
JNJ JOHNSON & JOHNSON 16.31 394.38B
NVO NOVO-NORDISK A/S-SPONS ADR 18.26 297.84B
NVS NOVARTIS AG-SPONSORED ADR 14.3 234.63B
AZN ASTRAZENECA PLC-SPONS ADR 16.14 217.62B
MRK MERCK & CO. INC. 10.54 206.22B
PFE PFIZER INC 7.67 139.95B
SNY SANOFI-ADR 10.66 118.15B
BMY BRISTOL-MYERS SQUIBB CO 6.39 95.41B
GSK GSK PLC-SPON ADR 8.6 77.10B
ZTS ZOETIS INC 25.18 67.48B
TAK TAKEDA PHARMACEUTIC-SP ADR 63.89 45.90B

About TLPH

Company Profile

TLPH logo image Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 13 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.

Company Info

TALPHERA INC

1850 Gateway Drive, Suite 175

San Mateo CALIFORNIA US

Employees: 13

TLPH Company Website

TLPH Investor Relations

Phone: 16502163500

TALPHERA INC / TLPH FAQ

What is the stock price of TALPHERA INC today?

The current stock price of TLPH is 0.44 USD. The price increased by 0.59% in the last trading session.


What is the ticker symbol for TALPHERA INC stock?

The exchange symbol of TALPHERA INC is TLPH and it is listed on the Nasdaq exchange.


On which exchange is TLPH stock listed?

TLPH stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for TALPHERA INC stock?

9 analysts have analysed TLPH and the average price target is 4.25 USD. This implies a price increase of 865.92% is expected in the next year compared to the current price of 0.44. Check the TALPHERA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TALPHERA INC worth?

TALPHERA INC (TLPH) has a market capitalization of 9.02M USD. This makes TLPH a Nano Cap stock.


How many employees does TALPHERA INC have?

TALPHERA INC (TLPH) currently has 13 employees.


What are the support and resistance levels for TALPHERA INC (TLPH) stock?

TALPHERA INC (TLPH) has a resistance level at 0.68. Check the full technical report for a detailed analysis of TLPH support and resistance levels.


Should I buy TALPHERA INC (TLPH) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TALPHERA INC (TLPH) stock pay dividends?

TLPH does not pay a dividend.


When does TALPHERA INC (TLPH) report earnings?

TALPHERA INC (TLPH) will report earnings on 2025-08-12.


What is the Price/Earnings (PE) ratio of TALPHERA INC (TLPH)?

TALPHERA INC (TLPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.45).


What is the Short Interest ratio of TALPHERA INC (TLPH) stock?

The outstanding short interest for TALPHERA INC (TLPH) is 1.2% of its float. Check the ownership tab for more information on the TLPH short interest.


TLPH Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to TLPH. When comparing the yearly performance of all stocks, TLPH is a bad performer in the overall market: 93.26% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

TLPH Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TLPH. TLPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TLPH Financial Highlights

Over the last trailing twelve months TLPH reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS increased by 49.44% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -77.65%
ROE -207.95%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%37.5%
Sales Q2Q%N/A
EPS 1Y (TTM)49.44%
Revenue 1Y (TTM)-100%

TLPH Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to TLPH. The Buy consensus is the average rating of analysts ratings from 9 analysts.


Ownership
Inst Owners31.31%
Ins Owners2.58%
Short Float %1.2%
Short Ratio0.7
Analysts
Analysts82.22
Price Target4.25 (865.91%)
EPS Next Y20%
Revenue Next YearN/A